MY-1076

CAS No. 3008262-76-5

MY-1076( —— )

Catalog No. M37087 CAS No. 3008262-76-5

MY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 46 In Stock
5MG 67 In Stock
10MG 107 In Stock
25MG 204 In Stock
50MG 333 In Stock
100MG 520 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MY-1076
  • Note
    Research use only, not for human use.
  • Brief Description
    MY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.
  • Description
    MY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.MY-1076 inhibited the proliferation of MGC-803, SGC-7901, HCT-116, and KYSE450 cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | YAP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3008262-76-5
  • Formula Weight
    539.57
  • Molecular Formula
    C29H33NO9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC1=C(OC)C=CC(CN(C2=CC(OC)=C(OC)C(OC)=C2)C(/C=C/C3=CC(OC)=C(OC)C(OC)=C3)=O)=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • DCH36_06

    DCH36_06? as a bona fide is a potent p300/CBP inhibitor

  • BTM-3528

    BTM-3528 is an activator of the mitochondrial protease OMA1 with anticancer activity.BTM-3528 activates the ISR via the mitochondrial protease OMA1, inducing OMA1-dependent cleavage of DELE1 and OPA1 and mitochondrial fragmentation.

  • Tafasitamab

    Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.